
FDA's Semaglutide Shortage Decision Survives Appeal: What It Means for Compounders, Peptide Sellers, and Med Spas Facing Federal Exposure
Still compounding or selling semaglutide? A federal appeals court just closed the shortage argument for good. Here is the exposure that replaced it.












